homovanillic acid and Delayed Effects, Prenatal Exposure
homovanillic acid has been researched along with Delayed Effects, Prenatal Exposure in 31 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, the exposure to new environmental condition elevated blood corticosterone levels and enhanced behavioral activities to a greater extent in the Dex group than in controls at 7 wk of life, suggesting that elevated glucocorticoid levels during the pregnancy mimicked prenatal mild stress, producing developmental alterations in brain monoamine metabolism, endocrine response, and behavior in adult offspring." | 3.69 | Prenatal dexamethasone exposure alters brain monoamine metabolism and adrenocortical response in rat offspring. ( Kamei, K; Kitera, K; Mikuni, M; Muneoka, K; Ogawa, T; Takahashi, K; Takigawa, M, 1997) |
| "Schizophrenia is probably ascribed to perinatal neurodevelopmental deficits, and its onset might be affected by environmental factors." | 1.62 | Preventive role of regular low-intensity exercise during adolescence in schizophrenia model mice with abnormal behaviors. ( Hata, T; Hiraga, T; Koizumi, H; Mouri, A; Nabeshima, T; Oharomari, LK; Okamoto, M; Shima, T; Soya, H; Yook, JS, 2021) |
| "Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder of mature and older individuals." | 1.36 | Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. ( Charlton, CG; King, J; Mackey, V; Muthian, G, 2010) |
| " Acute or chronic administration of methamphetamine elevates the levels of the extracellular monoamine neurotransmitters, such as dopamine." | 1.35 | Prenatal methamphetamine exposure affects the mesolimbic dopaminergic system and behavior in adult offspring. ( Bubenikova-Valesova, V; Hruba, L; Janovsky, M; Kacer, P; Rambousek, L; Schutova, B; Slamberova, R; Syslova, K, 2009) |
| "Styrene was evaluated to determine its neurochemical effects in the offspring of rats exposed during the gestation period." | 1.30 | Effects of prenatal exposure to styrene on neurochemical levels in rat brain. ( Ikeda, T; Katakura, Y; Kishi, R; Miyake, H, 1999) |
Research
Studies (31)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.45) | 18.7374 |
| 1990's | 11 (35.48) | 18.2507 |
| 2000's | 13 (41.94) | 29.6817 |
| 2010's | 4 (12.90) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Koizumi, H | 1 |
| Hiraga, T | 1 |
| Oharomari, LK | 1 |
| Hata, T | 1 |
| Shima, T | 1 |
| Yook, JS | 1 |
| Okamoto, M | 1 |
| Mouri, A | 1 |
| Nabeshima, T | 1 |
| Soya, H | 1 |
| Rose, KM | 1 |
| Parmar, MS | 1 |
| Cavanaugh, JE | 1 |
| Winter, C | 1 |
| Djodari-Irani, A | 1 |
| Sohr, R | 1 |
| Morgenstern, R | 1 |
| Feldon, J | 1 |
| Juckel, G | 1 |
| Meyer, U | 1 |
| Yokota, S | 1 |
| Mizuo, K | 1 |
| Moriya, N | 1 |
| Oshio, S | 1 |
| Sugawara, I | 1 |
| Takeda, K | 1 |
| Tekes, K | 1 |
| Gyenge, M | 1 |
| Hantos, M | 1 |
| Csaba, G | 1 |
| Ling, Z | 2 |
| Zhu, Y | 1 |
| Tong, CW | 1 |
| Snyder, JA | 1 |
| Lipton, JW | 1 |
| Carvey, PM | 2 |
| Wang, S | 1 |
| Yan, JY | 1 |
| Lo, YK | 1 |
| Bubenikova-Valesova, V | 1 |
| Kacer, P | 1 |
| Syslova, K | 1 |
| Rambousek, L | 1 |
| Janovsky, M | 1 |
| Schutova, B | 1 |
| Hruba, L | 1 |
| Slamberova, R | 1 |
| Muthian, G | 1 |
| Mackey, V | 1 |
| King, J | 1 |
| Charlton, CG | 1 |
| Hamilton, LR | 1 |
| Czoty, PW | 1 |
| Nader, MA | 1 |
| Phillips, PE | 1 |
| Johns, JM | 1 |
| Lubin, DA | 1 |
| Budygin, EA | 1 |
| Gainetdinov, RR | 1 |
| Lieberman, JA | 1 |
| Wightman, RM | 1 |
| Galineau, L | 1 |
| Belzung, C | 1 |
| Kodas, E | 1 |
| Bodard, S | 1 |
| Guilloteau, D | 1 |
| Chalon, S | 1 |
| Aldridge, JE | 1 |
| Meyer, A | 1 |
| Seidler, FJ | 2 |
| Slotkin, TA | 2 |
| Kreider, ML | 1 |
| Tate, CA | 1 |
| Yim, AJ | 1 |
| Miranda-Paiva, CM | 1 |
| Flório, JC | 1 |
| Oliveira, CA | 1 |
| Nasello, AG | 1 |
| Felicio, LF | 1 |
| Wang, CT | 1 |
| Shui, HA | 1 |
| Huang, RL | 1 |
| Tai, MY | 1 |
| Peng, MT | 1 |
| Tsai, YF | 1 |
| Romero, E | 1 |
| Guaza, C | 1 |
| Castellano, B | 1 |
| Borrell, J | 1 |
| Pérez-Otaño, I | 2 |
| Luquin, MR | 2 |
| Oset, C | 2 |
| Herrero, MT | 1 |
| Kupsch, A | 2 |
| Oertel, W | 2 |
| Obeso, JA | 2 |
| Del Río, J | 2 |
| Alonso, SJ | 1 |
| Navarro, E | 1 |
| Rodriguez, M | 1 |
| Needlman, R | 1 |
| Zuckerman, B | 1 |
| Anderson, GM | 1 |
| Mirochnick, M | 1 |
| Cohen, DJ | 1 |
| Silva-Araújo, A | 1 |
| Silva, MC | 1 |
| Simon, A | 1 |
| Nguyen-Legros, J | 1 |
| Ali, SF | 1 |
| Tavares, MA | 1 |
| Muneoka, K | 1 |
| Mikuni, M | 1 |
| Ogawa, T | 1 |
| Kitera, K | 1 |
| Kamei, K | 1 |
| Takigawa, M | 1 |
| Takahashi, K | 1 |
| Watanabe, M | 1 |
| Nonaka, R | 1 |
| Hagino, Y | 1 |
| Kodama, Y | 1 |
| Schneider, ML | 1 |
| Clarke, AS | 1 |
| Kraemer, GW | 1 |
| Roughton, EC | 1 |
| Lubach, GR | 1 |
| Rimm-Kaufman, S | 1 |
| Schmidt, D | 1 |
| Ebert, M | 1 |
| Katakura, Y | 1 |
| Kishi, R | 1 |
| Ikeda, T | 1 |
| Miyake, H | 1 |
| Du, W | 1 |
| Aloyo, VJ | 1 |
| Pazdelski, PS | 1 |
| Harvey, JA | 1 |
| Won, L | 1 |
| Bubula, N | 1 |
| Heller, A | 1 |
| Trinidad Herrero, M | 1 |
| Chiavegatto, S | 1 |
| Bernardi, MM | 1 |
| Rathbun, W | 1 |
| Druse, MJ | 1 |
| Guilarte, TR | 1 |
| Wagner, HN | 1 |
| Frost, JJ | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| An Open-Label Trial of Tocilizumab in Schizophrenia[NCT01696929] | Phase 1 | 8 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Change in Cognition
The Brief Assessment of Cognition in Schizophrenia (BACS) is the metric used to characterize cognition in this study. The BACS consists of 6 subscales: Verbal Memory (range 0-75), Working Memory (range 0-28), Motor Speed (range 0-100), Verbal Fluency (measure is total number of words generated in two 60 second trials), Attention and Processing speed (range 0-110), and Executive Function (range 0-22). For each subscale, higher scores reflect better cognition. For each subscale, a Standard Deviation Score was calculated based on normative data (Keefe et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research 102 (2008) 108-115). The BACS composite score is calculated as the average Standard Deviation Score of the 6 subscale scores. The change in BACS composite score was calculated as the BACS composite score at 8 weeks minus the BACS composite score at baseline. (NCT01696929)
Timeframe: Change in BACS composite score from baseline to 8 weeks
| Intervention | Change in BACS Composite Score (Mean) |
|---|---|
| Tocilizumab | 0.7 |
Change in Total Psychotic Symptoms
The Positive and Negative Symptoms Scale (PANSS) is the metric used to characterize psychotic symptoms in this study. The PANSS consists of 30 items, each scored 1-7. The range for the PANSS total score is 30-210. There are 3 subscales - PANSS positive score (range 7-49), PANSS negative score (range 7-49), and PANSS general score (range 16-112). PANSS total score is the summation of these 3 subscales. Higher values for the total and subscale scores reflect more severe psychopathology. A positive change in PANSS total score reflects an increase in psychopathology. A negative change in PANSS total score reflects a decrease in psychopathology. (NCT01696929)
Timeframe: Change in PANSS total score from baseline to 8 weeks
| Intervention | Change in PANSS Total Score (Mean) |
|---|---|
| Tocilizumab | -2.6 |
Other Studies
31 other studies available for homovanillic acid and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Preventive role of regular low-intensity exercise during adolescence in schizophrenia model mice with abnormal behaviors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Behavior, Animal; Disease Models, Animal; Dopa | 2021 |
Dietary supplementation with resveratrol protects against striatal dopaminergic deficits produced by in utero LPS exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dietary Supplements; Disease Models, Anima | 2014 |
Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Brain Diseases; Chromatography, High Press | 2009 |
Effect of prenatal exposure to diesel exhaust on dopaminergic system in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Circadian Rhythm; Dopamine; Female; Homovanillic Aci | 2009 |
Transgenerational hormonal imprinting caused by vitamin A and vitamin D treatment of newborn rats. Alterations in the biogenic amine contents of the adult brain.
Topics: Animals; Animals, Newborn; Brain Chemistry; Dopamine; Female; Homovanillic Acid; Hydroxyindoleacetic | 2009 |
Prenatal lipopolysaccharide does not accelerate progressive dopamine neuron loss in the rat as a result of normal aging.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Aging; Analysis of Variance; Animals; Body Weight; Brai | 2009 |
Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide.
Topics: Amygdala; Animals; Brain; Corpus Striatum; Dopamine; Female; Frontal Lobe; Hippocampus; Homovanillic | 2009 |
Prenatal methamphetamine exposure affects the mesolimbic dopaminergic system and behavior in adult offspring.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Disease Mod | 2009 |
Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Birth | 2010 |
Behavioral characterization of adult male and female rhesus monkeys exposed to cocaine throughout gestation.
Topics: Animals; Behavior, Animal; Cocaine; Conditioning, Psychological; Female; Homovanillic Acid; Hydroxyi | 2011 |
Presynaptic dopaminergic function is largely unaltered in mesolimbic and mesostriatal terminals of adult rats that were prenatally exposed to cocaine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoreceptors; Cocaine; Corpus Striatum; Dopamine; Dopamine | 2003 |
Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) exposure induces long-term alterations in the dopaminergic and serotonergic functions in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Age Fac | 2005 |
Alterations in central nervous system serotonergic and dopaminergic synaptic activity in adulthood after prenatal or neonatal chlorpyrifos exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Brain; Chlorpyrifos; Dopamine; Female; Ho | 2005 |
Critical prenatal and postnatal periods for persistent effects of dexamethasone on serotonergic and dopaminergic systems.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Developmental Disabilities; Dexamethasone; Dopamine; | 2006 |
A comparative study of morphine treatment regimen prior to mating and during late pregnancy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Brain | 2006 |
Sexual motivation is demasculinized, but not feminized, in prenatally stressed male rats.
Topics: Animals; Copulation; Dopamine; Female; Homovanillic Acid; Immobilization; Male; Motivation; Pregnanc | 2006 |
Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; An | 2010 |
Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; An | 2010 |
Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; An | 2010 |
Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; An | 2010 |
Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Callithrix; Dopamine; Enkephalin, Methionine; Female | 1995 |
Permanent dopaminergic alterations in the n. accumbens after prenatal stress.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Dopamine; Female; Functional Laterality; H | 1994 |
Cerebrospinal fluid monoamine precursors and metabolites in human neonates following in utero cocaine exposure: a preliminary study.
Topics: Biogenic Monoamines; Brain; Case-Control Studies; Cocaine; Dopamine; Dose-Response Relationship, Dru | 1993 |
The effects of prenatal exposure to cocaine on the dopaminergic cells in the rat retina. An immunocytochemical and neurochemical study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cocaine; Dopamine; Dopamine Uptake Inhibitors; Female; Homo | 1996 |
Prenatal dexamethasone exposure alters brain monoamine metabolism and adrenocortical response in rat offspring.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenal Cortex; Aging; Analysis of Variance; Animals; Biogenic Monoa | 1997 |
Effects of prenatal methylazoxymethanol treatment on striatal dopaminergic systems in rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Brain; Carrier Proteins; Corpus Striatum; | 1998 |
Prenatal stress alters brain biogenic amine levels in primates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Behavior, Animal; Biogenic Amines; Brain; Female; Ho | 1998 |
Effects of prenatal exposure to styrene on neurochemical levels in rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Birth Weight; Brain; Brain Chemistry; Dop | 1999 |
Effects of prenatal cocaine exposure on amphetamine-induced dopamine release in the caudate nucleus of the adult rabbit.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Caudate Nucleus; Cocaine; Dopamine; Dopamine U | 1999 |
Fetal exposure to methamphetamine in utero stimulates development of serotonergic neurons in three-dimensional reaggregate tissue culture.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine-Related Disorders; Animals; Brain; Cell Aggregation; Cel | 2002 |
Neurotoxic effect of prenatal exposure to MPTP on the dopaminergic systems of the marmoset brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adolescent; Animals; C | 1992 |
Effects of prenatal diphenhydramine exposure on dopaminergic function in adult rats.
Topics: Animals; Apomorphine; Copulation; Corpus Striatum; Diphenhydramine; Dopamine; Female; Homovanillic A | 1991 |
Dopamine, serotonin, and acid metabolites in brain regions from the developing offspring of ethanol-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Chemistry; Chromatography, High Pressure Liqui | 1985 |
Effects of perinatal vitamin B6 deficiency on dopaminergic neurochemistry.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Weight; Chromatography, High Pressure Liquid; Corpus S | 1987 |